Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Schoenfeld · SciRah

Researcher profile · Semantic Scholar

A. Schoenfeld

Share profile

A. Schoenfeld — researcher profile on SciRah

h-index: 37
Works: 192
Citations: 6,408

Most-cited papers

Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
D. Mathew, M. Marmarelis, C. Foley, J. Bauml +18 more
2024Science208 citations Open access
Semantic Scholar
A clinical benchmark of public self-supervised pathology foundation models
Gabriele Campanella, Shengjia Chen, Manbir Singh, Ruchika Verma +13 more
2024Nature Communications191 citations Open access
Semantic Scholar
Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
A. Schoenfeld, Sylvia M. Lee, Bernard Doger de Speville, S. Gettinger +12 more
2024Cancer Discovery102 citations Open access
Semantic Scholar
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy
Allison Betof Warner, Omid Hamid, Krishna V. Komanduri, R. Amaria +7 more
2024Journal for ImmunoTherapy of Cancer81 citations Open access
Semantic Scholar
Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy
A. Elkrief, E. O. Méndez-Salazar, J. Maillou, Chad M. Vanderbilt +11 more
2024npj Precision Oncology67 citations Open access
Semantic Scholar
Computational Pathology at Health System Scale - Self-Supervised Foundation Models from Three Billion Images
Gabriele Campanella, Ricky Kwan, Eugene Fluder, Jennifer Zeng +9 more
2023arXiv.org47 citations Open access
Semantic Scholar
Intratumoral Escherichia is associated with improved survival to single-agent immune checkpoint inhibition in patients with advanced non-small cell lung cancer
A. Elkrief, M. Montesion, S. Sivakumar, Caryn Hale +30 more
2024Journal of Clinical Oncology36 citations Open access
Semantic Scholar
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis
Pooja Middha, R. Thummalapalli, M. Betti, Lydia Yao +28 more
2024Nature Communications27 citations Open access
Semantic Scholar
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
J. Alessi, B. Ricciuti, Xinan Wang, Federica Pecci +14 more
2023Nature Communications26 citations Open access
Semantic Scholar
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-PD-(L)1 Plus Platinum Chemotherapy.
N. Leighl, L. Paz-Ares, D. Abreu, R. Hui +18 more
2025Journal of Thoracic Oncology24 citations Open access
Semantic Scholar
Gene copy deletion of STK11, KEAP1, and SMARCA4: clinicopathologic features and association with outcomes to immunotherapy +/- chemotherapy in nonsquamous non-small cell lung cancer.
Malini M. Gandhi, A. Elkrief, Catherine Gutierrez Moore, B. Ricciuti +13 more
2025Journal of Thoracic Oncology20 citations
Semantic Scholar
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab
B. Ricciuti, A. Elkrief, Jessica J. Lin, Jian-Jun Zhang +26 more
2024JTO Clinical and Research Reports20 citations Open access
Semantic Scholar
Benchmarking Embedding Aggregation Methods in Computational Pathology: A Clinical Data Perspective
Shengjia Chen, Gabriele Campanella, Abdulkadir Elmas, Aryeh Stock +7 more
2024COMPAY@MICCAI19 citations
Semantic Scholar
Pan-cancer analysis of biallelic inactivation patterns in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer
Mark Zucker, M. Perry, Samuel I. Gould, A. Elkrief +24 more
2024Cell17 citations Open access
Semantic Scholar
The Clinical TIL Experience in Melanoma: Past, Present, Future.
J. Smithy, A. Schoenfeld, Allison Betof Warner
2025Transplantation and Cellular Therapy16 citations Open access
Semantic Scholar
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multi-Center Retrospective Study
L. Hong, A. Di Federico, Bo-Lun Liu, Alissa J. Cooper +25 more
2025Journal of Thoracic Oncology14 citations Open access
Semantic Scholar
Ensemble learning of pathology foundation models for precision oncology
Xiang-De Luo, Xi-Yue Wang, Feyisope R. Eweje, Xiao-Ming Zhang +23 more
2025Cancer Cell12 citations Open access
Semantic Scholar
Entering a new era of tumor-infiltrating lymphocyte cell therapy innovation.
R. Amaria, Krishna V. Komanduri, A. Schoenfeld, Giridharan Ramsingh +2 more
2024Cytotherapy11 citations Open access
Semantic Scholar
Factors associated with disease progression after discontinuation of immune checkpoint inhibitors for immune-related toxicity in patients with advanced non-small cell lung cancer
Federica Pecci, R. Thummalapalli, S. Alden, B. Ricciuti +19 more
2025Clinical Cancer Research10 citations
Semantic Scholar
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events
Pooja Middha, R. Thummalapalli, Z. Quandt, K. Balaratnam +13 more
2024Journal for ImmunoTherapy of Cancer10 citations Open access
Semantic Scholar
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Mehmet Altan, Gilberto Lopes, T. J. N. Hiltermann, Ramaswamy Govindan +20 more
2024Clinical Cancer Research10 citations Open access
Semantic Scholar
Real‐world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event‐free survival
Alissa J. Cooper, E. Garbo, A. Arfé, Michael R. Conroy +13 more
2025Cancer9 citations
Semantic Scholar
Allele-specific HLA LOH in solid tumors: distinct patterns by tumor type and potential prognostic relevance
T. Sewastianik, C. Roy, M. Gormally, M. Montesion +7 more
2025Journal for ImmunoTherapy of Cancer8 citations Open access
Semantic Scholar
AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors.
Shaunica Mitchell, Binaish Khan, Francis Payumo, E. Chiorean +11 more
2024Journal of Clinical Oncology8 citations Open access
Semantic Scholar
Cancer type-specific variation in patterns of driver alterations across 50,000 tumors
C. Bandlamudi, D. Muldoon, I. de Bruijn, Mingxuan Zhang +85 more
2026Cancer Cell7 citations Open access
Semantic Scholar
1488 A multicenter phase 2 trial of lifileucel plus pembrolizumab in patients with checkpoint inhibitor-naive metastatic NSCLC: updated results
B. Creelan, K. He, Edward B. Garon, Jason Chesney +10 more
2024Late-Breaking Abstracts7 citations Open access
Semantic Scholar
Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies.
M. Gormally, Monica F. Chen, Anne Marie Noronha, Kristalla Panageas +23 more
2024JAMA Oncology6 citations Open access
Semantic Scholar
Safety, tolerability, and preliminary efficacy results of a phase 1 study of LB2102, a dnTGFβRII armored DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC).
Jacob M. Sands, A. Chiappori, B. Creelan, P. Schwarzenberger +8 more
2025Journal of Clinical Oncology5 citations
Semantic Scholar
Optimal Systemic Treatment and Real-World Clinical Application of ctDNA in Patients with Metastatic HER2-Mutant Lung Cancer
Si-Yang Liu, T. Erazo, J. Jee, A. Arfé +29 more
2024European Journal of Cancer5 citations Open access
Semantic Scholar
A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors.
A. Schoenfeld, Allison Betof Warner, J. Chesney, S. Thomas +10 more
2024Journal of Clinical Oncology5 citations Open access
Semantic Scholar
Abstract CT183: Initial results from a phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132)
B. Izar, D. Zamarin, D. Spigel, C. Hoimes +17 more
2024Cancer Research5 citations
Semantic Scholar
702 Phase 1 study of DLL3-directed chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer
Jacob Sands, A. Schoenfeld, P. Schwarzenberger, Christopher Delcorral +8 more
2023Regular and Young Investigator Award Abstracts5 citations Open access
Semantic Scholar
Initial phase 1 study results of NT-175 engineered T-cell therapy in TP53 R175H–mutated unresectable advanced solid tumors.
R. Surana, A. Schoenfeld, M. Kamgar, E. Dumbrava +16 more
2026Journal of Clinical Oncology4 citations
Semantic Scholar
TTF-1 expression in lung adenocarcinoma: clinicopathologic, genomic, and immunophenotypic correlates and outcomes to immunotherapy-based treatments and KRASG12C inhibitors.
A. Di Federico, L. Hong, A. Elkrief, R. Thummalapalli +44 more
2026Journal of Thoracic Oncology4 citations
Semantic Scholar
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients.
A. Barrichello, A. Elkrief, B. Ricciuti, Teja Ganta +31 more
2025Clinical Lung Cancer4 citations Open access
Semantic Scholar
Abstract CT109: A first-in-human phase 1 study of LY4050784, an oral, potent, and selective SMARCA2 inhibitor, in patients with advanced solid tumors with SMARCA4 alterations (Trial in Progress)
T. Yap, A. Spira, A. Schoenfeld, V. Subbiah +13 more
2025Cancer Research4 citations
Semantic Scholar
Infections in Patients with Solid Tumors Undergoing Adoptive Cellular Therapy.
Viswatej Avutu, Jumanah N. Algazaq, K. Seier, R. Desir-Camille +13 more
2025Transplantation and Cellular Therapy4 citations
Semantic Scholar
Association of the time of day of chemoradiotherapy and durvalumab with tumor control in lung cancer.
M. McMillan, A. Shepherd, Alissa J. Cooper, A. Schoenfeld +7 more
2024Radiotherapy and Oncology4 citations Open access
Semantic Scholar
Timing Is of the Essence: Sequencing Immune Checkpoint Blockade and Radiotherapy for Success in Lung Cancer.
Florence K. Keane, A. Schoenfeld
2026Journal of Clinical Oncology3 citations
Semantic Scholar
Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancer
Xinan Wang, B. Ricciuti, A. Elkrief, J. Alessi +12 more
2025Journal for ImmunoTherapy of Cancer3 citations Open access
Semantic Scholar
Preliminary results from an ongoing phase 1 study of LB2102, a dnTGFBR2-armored DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory SCLC or LCNEC.
Zhonglin Hao, A. Chiappori, B. Creelan, Reinhold Munker +9 more
2026Journal of Clinical Oncology2 citations
Semantic Scholar
Impact of DLL3 expression and tumor subtype on response to tarlatamab.
J. Ross, J. Lee, S. Cascarino, M. Baine +11 more
2026Journal of Clinical Oncology2 citations
Semantic Scholar
Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Non-Squamous Non-Small Cell Lung Cancer Treated with Chemoradiation and Immunotherapy.
N. Mankuzhy, Valentina Santo, Jacob Y. Shin, T. Chaunzwa +19 more
2026Journal of Thoracic Oncology2 citations
Semantic Scholar
Use of a large language model (LLM) for pan-cancer automated detection of anti-cancer therapy toxicities and translational toxicity research.
Z. Bakouny, N. Ahmed, Christopher J. Fong, Afsana Rahman +15 more
2025Journal of Clinical Oncology2 citations
Semantic Scholar
Phase 2, multicenter study of frontline maintenance therapy with lifileucel plus pembrolizumab in advanced non-small cell lung cancer.
B. Creelan, S. Gettinger, J. Chesney, A. Sukari +16 more
2025Journal of Clinical Oncology2 citations
Semantic Scholar
Abstract CT244: Trial in progress: Phase 1/2 study of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced solid tumors
A. Shoushtari, A. Schoenfeld, K. He, J. Chesney +12 more
2025Cancer Research2 citations
Semantic Scholar
Abstract CT076: AFNT-211: A phase1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8α/β coreceptor; and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors
Shaunica Mitchell, Binaish Khan, Francis Payumo, E. Chiorean +11 more
2024Cancer Research2 citations
Semantic Scholar
Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer.
K. Betts, Sophie Gao, Saurabh Ray, A. Schoenfeld
2024Future Oncology2 citations Open access
Semantic Scholar
Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.
C. Bandlamudi, D. Muldoon, I. de Bruijn, Mingxuan Zhang +85 more
2026Cancer Cell1 citations Open access
Semantic Scholar
Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies.
Jonas Willmann, E. Dee, L. Hendriks, Nikolaos M. Dimitriou +19 more
2026Journal of Clinical Oncology1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Elkrief×10
Invite
A. Elkrief — researcher profile on SciRah
J. Alessi×9
Invite
J. Alessi — researcher profile on SciRah
Federica Pecci×9
Invite
Federica Pecci — researcher profile on SciRah
C. Rudin×8
Invite
C. Rudin — researcher profile on SciRah

×8

Invite

B. Ricciuti — researcher profile on SciRah

A. Di Federico×8

Invite

A. Di Federico — researcher profile on SciRah

Invite

M. Awad — researcher profile on SciRah

Invite

A. Drilon — researcher profile on SciRah

N. Shaverdian×5

Invite

N. Shaverdian — researcher profile on SciRah

C. Klebanoff×5

Invite

C. Klebanoff — researcher profile on SciRah

C. Vanderbilt×4

Invite

C. Vanderbilt — researcher profile on SciRah

Invite

H. Rizvi — researcher profile on SciRah